S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
China Has Stunning Lithium Chokehold On U.S. (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
China Has Stunning Lithium Chokehold On U.S. (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
3 Dividend Kings With Royally Good Upside
China Has Stunning Lithium Chokehold On U.S. (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
China Has Stunning Lithium Chokehold On U.S. (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
China Has Stunning Lithium Chokehold On U.S. (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
3 Dividend Kings With Royally Good Upside
China Has Stunning Lithium Chokehold On U.S. (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
China Has Stunning Lithium Chokehold On U.S. (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
China Has Stunning Lithium Chokehold On U.S. (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
3 Dividend Kings With Royally Good Upside
China Has Stunning Lithium Chokehold On U.S. (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
China Has Stunning Lithium Chokehold On U.S. (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
China Has Stunning Lithium Chokehold On U.S. (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
3 Dividend Kings With Royally Good Upside
China Has Stunning Lithium Chokehold On U.S. (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
NASDAQ:CTIC

CTI BioPharma - CTIC Stock Forecast, Price & News

$5.56
+0.05 (+0.91%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.46
$5.71
50-Day Range
$4.45
$6.17
52-Week Range
$1.74
$7.80
Volume
2.14 million shs
Average Volume
3.15 million shs
Market Capitalization
$705.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

CTI BioPharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
97.8% Upside
$11.00 Price Target
Short Interest
Healthy
13.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$3.05 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.71) to $0.02 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

638th out of 1,027 stocks

Pharmaceutical Preparations Industry

304th out of 503 stocks

CTIC stock logo

About CTI BioPharma (NASDAQ:CTIC) Stock

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CTIC Stock News Headlines

CTI BioPharma to Present at Upcoming November Conferences
CTI BioPharma: Q3 Earnings Snapshot
CTI BioPharma's VONJO May Be Coming Of Age
Analyst Ratings for CTI BioPharma
Why CTI BioPharma Stock Crushed the Market Today
Where CTI BioPharma Stands With Analysts
Why CTI BioPharma Stock Withered on Wednesday
Analyst Ratings: What Are They?
What 4 Analyst Ratings Have To Say About CTI BioPharma
CTI BioPharma: Q2 Earnings Insights
CTI BioPharma: One Trick Pony Ready To Perform
See More Headlines
Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CTIC Company Calendar

Last Earnings
8/05/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTIC
Previous Symbol
NASDAQ:CTICD
Employees
22
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+97.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-97,910,000.00
Pretax Margin
-341.77%

Debt

Sales & Book Value

Annual Sales
$3.35 million
Book Value
$0.04 per share

Miscellaneous

Free Float
113,951,000
Market Cap
$705.51 million
Optionable
Optionable
Beta
0.85

Social Links


Key Executives

  • Dr. Adam R. Craig M.B.A. (Age 56)
    M.D., Ph.D., Pres, CEO, Interim Chief Medical Officer & Director
    Comp: $1.02M
  • Mr. David H. Kirske (Age 68)
    Exec. VP, CFO & Sec.
    Comp: $542.34k
  • Mr. Ed Bell
    Sr. Director of Investor Relations
  • Mr. James K. Fong (Age 60)
    Exec. VP & Chief Commercial Officer
  • Mr. Bruce K. Bennett Jr. (Age 70)
    Sr. VP Global Pharmaceutical Operations
  • Mr. John P. Volpone
    Exec. VP & Chief of Staff
  • Dr. Jennifer A. Smith
    Sr. VP of Biometrics













CTIC Stock - Frequently Asked Questions

Should I buy or sell CTI BioPharma stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTIC shares.
View CTIC analyst ratings
or view top-rated stocks.

What is CTI BioPharma's stock price forecast for 2023?

8 analysts have issued 12 month price objectives for CTI BioPharma's shares. Their CTIC share price forecasts range from $9.00 to $13.00. On average, they anticipate the company's share price to reach $11.00 in the next year. This suggests a possible upside of 97.8% from the stock's current price.
View analysts price targets for CTIC
or view top-rated stocks among Wall Street analysts.

How have CTIC shares performed in 2022?

CTI BioPharma's stock was trading at $2.48 at the beginning of the year. Since then, CTIC stock has increased by 124.2% and is now trading at $5.56.
View the best growth stocks for 2022 here
.

When is CTI BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our CTIC earnings forecast
.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp. (NASDAQ:CTIC) issued its quarterly earnings data on Thursday, August, 5th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01.

When did CTI BioPharma's stock split?

Shares of CTI BioPharma reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is James A. Bianco's approval rating as CTI BioPharma's CEO?

8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of CTI BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

Who are CTI BioPharma's major shareholders?

CTI BioPharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (10.83%), BVF Inc. IL (6.95%), BlackRock Inc. (5.20%), Stonepine Capital Management LLC (4.47%), Vanguard Group Inc. (3.77%) and Bleichroeder LP (3.11%). Insiders that own company stock include Adam R Craig, Bvf Partners L P/Il, David Kirske, Michael A Metzger and Orbimed Advisors Llc.
View institutional ownership trends
.

How do I buy shares of CTI BioPharma?

Shares of CTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $5.56.

How much money does CTI BioPharma make?

CTI BioPharma (NASDAQ:CTIC) has a market capitalization of $705.53 million and generates $3.35 million in revenue each year. The biopharmaceutical company earns $-97,910,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The official website for the company is www.ctibiopharma.com. The biopharmaceutical company can be reached via phone at (206) 282-7100, via email at invest@ctibiopharma.com, or via fax at 206-284-6206.

This page (NASDAQ:CTIC) was last updated on 12/8/2022 by MarketBeat.com Staff